<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="559">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000424606</actrnumber>
  <trial_identification>
    <studytitle>Dendritic cell vaccination trial for hormone refractory prostate cancer with autologous tumour as the antigen</studytitle>
    <scientifictitle>Dendritic cell vaccination trial for hormone refractory prostate cancer with autologous tumour as the antigen to assess safety and effect on disease progression.</scientifictitle>
    <utrn />
    <trialacronym>NRQ03J1</trialacronym>
    <secondaryid>Queensland Institute of Medical Research (QIMR): QIMR P647</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hormone refractory prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cultured autologous dendritic cells (DC) processed to present autologous prostate cancer antigens for treatment of hormone refractory prostate cancer.  Vaccines are administered at 2 weekly intervals for 10 weeks and then 6-weekly for up to one year.</interventions>
    <comparator>None, phase I, single arm study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety assessed at each vaccination</outcome>
      <timepoint>Every two weeks for 10 weeks and then every 6 weeks for up to 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PSA levels tested at each vaccination</outcome>
      <timepoint>Every two weeks for 10 weeks and then every 6 weeks for up to 1 year.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumour stasis/regression assessed by radiography performed either.</outcome>
      <timepoint>At final assessment or as clinically indicated based on PSA levels.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Histologically proven prostatic Cancer, Maintenance hormone monotherapy, Serum PSA titres rising on 2 consecutive analyses, Minimum 5g of tumour-containing tissue.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>ECOG status &gt;1, Significantly abnormal Haematological parameters, History of autoimmune disease or previous long-term use of immunosuppressive therapy, Positive serology for HIV, Hep C or B, Significant non-malignant disease, Psychiatric, addictive or any conditions which compromise ability to participate in trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>30/06/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Queensland Institute of Medical Research (QIMR)</primarysponsorname>
    <primarysponsoraddress>300 Herston Rd, Herston</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Atlantic Philanthropies</fundingname>
      <fundingaddress>16 Wesley St, Hamilton HM GX</fundingaddress>
      <fundingcountry>Bermuda</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland Institute of Medical Research</ethicname>
      <ethicaddress>Herston, QLD 4006</ethicaddress>
      <ethicapprovaldate>6/06/2003</ethicapprovaldate>
      <hrec>EC00278</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Womens' Hospital</ethicname>
      <ethicaddress>Herston, QLD 4029</ethicaddress>
      <ethicapprovaldate>26/05/2003</ethicapprovaldate>
      <hrec>EC00172</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Schmidt</name>
      <address>Queensland Institute of Medical Research
300 Herston Road
Herston QLD 4006</address>
      <phone>+61 7 33620313</phone>
      <fax>+61 7 38453510</fax>
      <email>Chris.Schmidt@qimr.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Betty Scells</name>
      <address>University of Queensland
Clinical Sciences Building
Royal Brisbane and Womens' Hospital
Herston QLD 4006</address>
      <phone>+61 7 33655233</phone>
      <fax>+61 7 33655559</fax>
      <email>b.scells@mailbox.uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Agnieszka Mitchell</name>
      <address>Queensland Institute of Medical Research, 300 Herston Rd, Herston 4006</address>
      <phone>07 3362 0241</phone>
      <fax>07 3362 0109</fax>
      <email>Agnieszka.Mitchell@qimr.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>